LON:HIK - Hikma Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 1,346.50 +7.00 (+0.52 %)
(As of 05/25/2018 04:00 PM ET)
Previous CloseGBX 1,346.50
Today's RangeGBX 1,320.50 - GBX 1,375
52-Week RangeGBX 814.20 - GBX 2,346
Volume454,477 shs
Average Volume822,138 shs
Market Capitalization£2.67 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals logoHikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segment's principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segment's principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segment's principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolLON:HIK
CUSIPN/A
Phone+44-20-73992760

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins7.82%
Return on Equity5.69%
Return on Assets3.19%

Miscellaneous

EmployeesN/A
Outstanding Shares240,660,000

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Wednesday, March 14th. Shareholders of record on Thursday, April 5th will be given a dividend of GBX 0.23 per share on Thursday, May 24th. This represents a yield of 1.47%. The ex-dividend date of this dividend is Thursday, April 5th. This is an increase from Hikma Pharmaceuticals's previous dividend of $0.22. The official announcement can be seen at this link. View Hikma Pharmaceuticals' Dividend History.

What price target have analysts set for HIK?

9 brokers have issued 1 year price objectives for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 850 to GBX 1,560. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 1,161.33 in the next twelve months. View Analyst Ratings for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
  • Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

Has Hikma Pharmaceuticals been receiving favorable news coverage?

News stories about HIK stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of 0.11 on Accern's scale. They also gave news stories about the company an impact score of 45.04 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,346.50.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £2.67 billion.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


MarketBeat Community Rating for Hikma Pharmaceuticals (HIK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  466 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  744
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hikma Pharmaceuticals (LON:HIK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Hikma Pharmaceuticals in the last 12 months. Their average twelve-month price target is GBX 1,161.33The high price target for HIK is GBX 1,560 and the low price target for HIK is GBX 850. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.112.112.30
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 1,161.33GBX 1,107.44GBX 1,181.67GBX 1,367.60

Hikma Pharmaceuticals (LON:HIK) Consensus Price Target History

Price Target History for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/21/2018BarclaysReiterated RatingUnderweightView Rating Details
5/18/2018Numis SecuritiesDowngradeAddGBX 1,300 ➝ GBX 1,560View Rating Details
5/18/2018Jefferies GroupReiterated RatingHoldGBX 997View Rating Details
5/18/2018Peel HuntReiterated RatingHoldView Rating Details
5/1/2018CitigroupBoost Price TargetBuyGBX 1,250 ➝ GBX 1,475View Rating Details
3/15/2018Morgan StanleyBoost Price TargetEqual weightGBX 1,000 ➝ GBX 1,050View Rating Details
3/15/2018JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,000 ➝ GBX 1,050View Rating Details
11/9/2017Stifel NicolausLower Price TargetHoldGBX 1,320 ➝ GBX 1,000View Rating Details
8/22/2017Goldman Sachs GroupDowngradeNeutralGBX 2,600 ➝ GBX 1,310View Rating Details
11/30/2016AlphaValueReiterated RatingBuyGBX 2,431View Rating Details
(Data available from 5/26/2016 forward)

Earnings

Dividends

Hikma Pharmaceuticals (LON:HIK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/14/2018$0.231.47%4/5/20184/5/20185/24/2018
3/15/2017€0.220.78%4/6/20174/6/20175/25/2017
3/11/2015€0.210.64%4/16/20154/16/20155/21/2015
(Data available from 1/1/2013 forward)

Insider Trades

Hikma Pharmaceuticals (LON HIK) Insider Trading and Institutional Ownership History

Insider Trading History for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON HIK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2018John J. CastellaniInsiderBuy1,000GBX 1,377£13,770
12/19/2016Ali Al-HusryInsiderBuy50,000GBX 1,790£895,000
12/16/2016Mazen DarwazahInsiderBuy90,730GBX 1,849£1,677,597.70
12/12/2016Ali Al-HusryInsiderBuy50,000GBX 1,707£853,500
12/9/2016Ali Al-HusryInsiderBuy50,000GBX 1,723£861,500
12/6/2016Ali Al-HusryInsiderBuy100,000GBX 1,682£1,682,000
12/5/2016Ali Al-HusryInsiderBuy50,000GBX 1,674£837,000
12/2/2016Mazen DarwazahInsiderBuy50,000GBX 1,662£831,000
12/1/2016Mazen DarwazahInsiderBuy50,000GBX 1,674£837,000
11/30/2016Said DarwazahInsiderBuy50,000GBX 1,662£831,000
9/28/2016Said DarwazahInsiderBuy10,000GBX 2,085£208,500
9/27/2016Ali Al-HusryInsiderBuy50,000GBX 2,094£1,047,000
9/26/2016Said DarwazahInsiderBuy50,000GBX 2,078£1,039,000
9/23/2016Ali Al-HusryInsiderBuy50,000GBX 2,099£1,049,500
9/21/2016Ali Al-HusryInsiderBuy50,000GBX 2,138£1,069,000
9/16/2016Al-Husry,AliInsiderBuy50,000GBX 2,119£1,059,500
9/15/2016Darwazah,SaidInsiderBuy70,251GBX 2,122£1,490,726.22
9/8/2016Darwazah,MazenInsiderBuy150,000GBX 2,162£3,243,000
9/6/2016Darwazah,MazenInsiderBuy155,991GBX 2,194£3,422,442.54
8/31/2016Al-Husry,AliInsiderBuy140,000GBX 2,150£3,010,000
8/26/2016Darwazah,SaidInsiderBuy200,000GBX 2,160£4,320,000
6/24/2016Darwazah,MazenInsiderBuy150,000GBX 2,200£3,300,000
6/17/2016Al-Husry,AliInsiderBuy70,000GBX 22£15,400
5/9/2016Darwazah,SaidInsiderBuy17,440GBX 2,228£388,563.20
4/26/2016Darwazah,SaidInsiderBuy10,000GBX 2,260£226,000
4/25/2016Darwazah,SaidInsiderBuy10,000GBX 2,324£232,400
4/22/2016Darwazah,SaidInsiderBuy30,000GBX 2,325£697,500
4/20/2016Darwazah,SaidInsiderBuy30,000GBX 2,271£681,300
4/19/2016Darwazah,SaidInsiderBuy30,000GBX 2,266£679,800
4/11/2016J. Castellani,JohnInsiderBuy2,500GBX 2,103£52,575
4/7/2016Darwazah,MazenInsiderBuy60,000GBX 2,118£1,270,800
4/5/2016Darwazah,SaidInsiderBuy30,000GBX 2,055£616,500
3/31/2016Darwazah,SaidInsiderBuy30,000GBX 1,972£591,600
3/24/2016Butler,PatInsiderBuy2,500GBX 1,920£48,000
3/21/2016Pickering ,RobertInsiderBuy2,500GBX 1,856£46,400
8/27/2015Kirby,PamelaInsiderBuy3,317GBX 2,264£75,096.88
(Data available from 1/1/2013 forward)

Headlines

Hikma Pharmaceuticals (LON HIK) News Headlines

Source:
DateHeadline
Global Inhalation Anesthesia Market Growth Opportunities: Jiangsu Hengrui Medicine Co. Ltd., Lunan Pharmaceutical Group Co.Global Inhalation Anesthesia Market Growth Opportunities: Jiangsu Hengrui Medicine Co. Ltd., Lunan Pharmaceutical Group Co.
www.marketwatch.com - May 24 at 8:27 AM
Hikma Pharmaceuticals (HIK) Given Average Recommendation of "Hold" by BrokeragesHikma Pharmaceuticals (HIK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 24 at 5:47 AM
Hikma Pharmaceuticals (HIK) Insider John J. Castellani Acquires 1,000 SharesHikma Pharmaceuticals (HIK) Insider John J. Castellani Acquires 1,000 Shares
www.americanbankingnews.com - May 23 at 7:24 AM
Barclays Reiterates Underweight Rating for Hikma Pharmaceuticals (HIK)Barclays Reiterates Underweight Rating for Hikma Pharmaceuticals (HIK)
www.americanbankingnews.com - May 21 at 10:00 AM
Peel Hunt Reiterates Hold Rating for Hikma Pharmaceuticals (HIK)Peel Hunt Reiterates Hold Rating for Hikma Pharmaceuticals (HIK)
www.americanbankingnews.com - May 18 at 5:15 PM
Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Jefferies GroupHikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Jefferies Group
www.americanbankingnews.com - May 18 at 10:17 AM
Numis Securities Lowers Hikma Pharmaceuticals (HIK) to AddNumis Securities Lowers Hikma Pharmaceuticals (HIK) to Add
www.americanbankingnews.com - May 18 at 10:16 AM
Hikma Pharma Backs FY18 Guidance For Injectables, Generics, Branded SegmentsHikma Pharma Backs FY18 Guidance For Injectables, Generics, Branded Segments
www.nasdaq.com - May 18 at 8:52 AM
Hikma makes encouraging start to year, shareholders toldHikma makes 'encouraging' start to year, shareholders told
www.lse.co.uk - May 18 at 8:52 AM
TOP NEWS: Hikma Pharmaceuticals Keeps 2018 Guidance With Strong StartTOP NEWS: Hikma Pharmaceuticals Keeps 2018 Guidance With Strong Start
www.morningstar.co.uk - May 18 at 8:52 AM
Hikma reaffirms full-year revenue forecast, cites better generics businessHikma reaffirms full-year revenue forecast, cites better generics business
finance.yahoo.com - May 18 at 8:52 AM
Basilea Pharmaceutica AG: Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLCBasilea Pharmaceutica AG: Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
www.finanznachrichten.de - May 16 at 8:30 AM
Hospitals in US sound alarm on impending chemotherapy shortagesHospitals in US sound alarm on impending chemotherapy shortages
www.ft.com - May 9 at 8:27 AM
[$$] Hospitals in US sound alarm on impending chemotherapy shortages[$$] Hospitals in US sound alarm on impending chemotherapy shortages
finance.yahoo.com - May 9 at 8:27 AM
Hikma Pharmas West-Ward Pharma Launches Methotrexate For InjectionHikma Pharma's West-Ward Pharma Launches Methotrexate For Injection
www.nasdaq.com - May 3 at 8:24 AM
Hikma Pharmaceuticals Subsidiary West-Ward Launches Cancer Drug In USHikma Pharmaceuticals Subsidiary West-Ward Launches Cancer Drug In US
www.morningstar.co.uk - May 3 at 8:24 AM
Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,475 by Analysts at CitigroupHikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,475 by Analysts at Citigroup
www.americanbankingnews.com - May 1 at 6:46 AM
Hikma Pharmaceuticals (HIK) Receives Average Recommendation of "Hold" from AnalystsHikma Pharmaceuticals (HIK) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 29 at 5:31 AM
Hikma Pharmaceuticals Signs Licensing Agreement To Supply EnoxaparinHikma Pharmaceuticals Signs Licensing Agreement To Supply Enoxaparin
www.morningstar.co.uk - April 24 at 8:25 AM
Apotex next: Can Barry Shermans company thrive again?Apotex next: Can Barry Sherman's company thrive again?
www.theglobeandmail.com - April 21 at 8:26 AM
BRIEF-Hikma Pharmaceuticals Says US Subsidiary Launches Dexrazoxane For InjectionBRIEF-Hikma Pharmaceuticals Says US Subsidiary Launches Dexrazoxane For Injection
www.reuters.com - April 21 at 8:26 AM
Hikma Pharmaceuticals (HIK) Earns "Neutral" Rating from JPMorgan ChaseHikma Pharmaceuticals (HIK) Earns "Neutral" Rating from JPMorgan Chase
www.americanbankingnews.com - April 20 at 5:18 PM
FTSE 250 movers: Hikma rallies; Countryside hit by Oaktree stake saleFTSE 250 movers: Hikma rallies; Countryside hit by Oaktree stake sale
www.lse.co.uk - April 20 at 5:16 PM
Hikma Pharmaceuticals (HIK) Price Target Lowered to GBX 1,410 at Hikma Pharmaceuticals (HIK) Price Target Lowered to GBX 1,410 at
www.americanbankingnews.com - April 20 at 4:48 PM
Hikma Subsidiary West-Ward Launches Dexrazoxane For InjectionHikma Subsidiary West-Ward Launches Dexrazoxane For Injection
www.morningstar.co.uk - April 20 at 8:34 AM
Hikma Pharma Launches Dexrazoxane For InjectionHikma Pharma Launches Dexrazoxane For Injection
www.nasdaq.com - April 20 at 8:34 AM
Hikma Pharmaceuticals (HIK) Stock Rating Lowered by Morgan StanleyHikma Pharmaceuticals (HIK) Stock Rating Lowered by Morgan Stanley
www.americanbankingnews.com - April 14 at 12:53 PM
Estimating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)Estimating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
finance.yahoo.com - April 13 at 8:31 AM
Hikma Pharmaceuticals (HIK) Lowered to Neutral at Goldman SachsHikma Pharmaceuticals (HIK) Lowered to Neutral at Goldman Sachs
www.americanbankingnews.com - April 10 at 8:37 AM
Hikma Pharmaceuticals (HIK) Given Hold Rating at Peel HuntHikma Pharmaceuticals (HIK) Given Hold Rating at Peel Hunt
www.americanbankingnews.com - April 4 at 12:31 PM
Hikma Pharmaceuticals (HIK) Receives Consensus Recommendation of "Hold" from AnalystsHikma Pharmaceuticals (HIK) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 5:31 AM
Hikma Pharmaceuticals (HIK) "Hold" Rating Reaffirmed at Peel HuntHikma Pharmaceuticals' (HIK) "Hold" Rating Reaffirmed at Peel Hunt
www.americanbankingnews.com - April 3 at 10:30 PM
Propeller Health Publishes Results From a Large Public Health Study on Asthma; Successfully Reduces the Burden of Asthma in LouisvillePropeller Health Publishes Results From a Large Public Health Study on Asthma; Successfully Reduces the Burden of Asthma in Louisville
finance.yahoo.com - April 3 at 8:32 AM
Peel Hunt Reiterates "Hold" Rating for Hikma Pharmaceuticals (HIK)Peel Hunt Reiterates "Hold" Rating for Hikma Pharmaceuticals (HIK)
www.americanbankingnews.com - March 31 at 7:42 PM
Hikma Pharmaceuticals (HIK) Hold Rating Reaffirmed at Jefferies GroupHikma Pharmaceuticals' (HIK) Hold Rating Reaffirmed at Jefferies Group
www.americanbankingnews.com - March 31 at 7:42 PM
Hikma Pharmaceuticals (HIK) Given New GBX 865 Price Target at Hikma Pharmaceuticals (HIK) Given New GBX 865 Price Target at
www.americanbankingnews.com - March 31 at 4:22 PM
Hikma Pharmaceuticals (HIK) to Issue Dividend of $0.23Hikma Pharmaceuticals (HIK) to Issue Dividend of $0.23
www.americanbankingnews.com - March 31 at 8:58 AM
Hikma Pharmaceuticals (HIK) Lowered to Underperform at Jefferies GroupHikma Pharmaceuticals (HIK) Lowered to Underperform at Jefferies Group
www.americanbankingnews.com - March 29 at 5:16 PM
Jefferies Group Reiterates Underperform Rating for Hikma Pharmaceuticals (HIK)Jefferies Group Reiterates Underperform Rating for Hikma Pharmaceuticals (HIK)
www.americanbankingnews.com - March 27 at 10:22 PM
Hikma Pharmaceuticals (HIK) Earns "Hold" Rating from Peel HuntHikma Pharmaceuticals (HIK) Earns "Hold" Rating from Peel Hunt
www.americanbankingnews.com - March 26 at 12:04 AM
2 FTSE 250 pharma stocks I’d buy today and hold for another five years2 FTSE 250 pharma stocks I’d buy today and hold for another five years
www.fool.co.uk - March 24 at 5:09 PM
Hikma Pharmaceuticals (HIK) PT Lowered to GBX 1,160Hikma Pharmaceuticals (HIK) PT Lowered to GBX 1,160
www.americanbankingnews.com - March 24 at 12:54 PM
Barclays Raises Hikma Pharmaceuticals (HIK) Price Target to GBX 850Barclays Raises Hikma Pharmaceuticals (HIK) Price Target to GBX 850
www.americanbankingnews.com - March 19 at 6:46 PM
Hikma Pharmaceuticals (HIK) Buy Rating Reiterated at Numis SecuritiesHikma Pharmaceuticals' (HIK) Buy Rating Reiterated at Numis Securities
www.americanbankingnews.com - March 17 at 11:10 PM
Jefferies Group Upgrades Hikma Pharmaceuticals (HIK) to HoldJefferies Group Upgrades Hikma Pharmaceuticals (HIK) to Hold
www.americanbankingnews.com - March 15 at 5:56 PM
Hikma Pharmaceuticals (HIK) Upgraded at CitigroupHikma Pharmaceuticals (HIK) Upgraded at Citigroup
www.americanbankingnews.com - March 15 at 5:04 PM
Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at Morgan StanleyHikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at Morgan Stanley
www.americanbankingnews.com - March 15 at 11:55 AM
Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at JPMorgan Chase & Co.Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at JPMorgan Chase & Co.
www.americanbankingnews.com - March 15 at 9:09 AM
Hikma Pharmaceuticals (HKMPF) CEO Siggi Olafsson on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaHikma Pharmaceuticals' (HKMPF) CEO Siggi Olafsson on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 15 at 8:26 AM
[$$] Stocks to watch: PZ Cussons, Old Mutual, Dufry, Tesco, Hikma[$$] Stocks to watch: PZ Cussons, Old Mutual, Dufry, Tesco, Hikma
finance.yahoo.com - March 15 at 8:26 AM

SEC Filings

Hikma Pharmaceuticals (LON:HIK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Hikma Pharmaceuticals (LON HIK) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.